Terminated PHASE2 INTERVENTIONAL 2-arm NCT00444834

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

A Phase II, Multi-center, Multiple-dose, Double-blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and an Immediate-Release Carvedilol (IRC) Formulation in Patients With Primary Hypertension

Sponsor: Egalet Ltd

Conditions Hypertension

Interventions Carvedilol

Updated 5 times since 2017 Last updated: Aug 26, 2016 Started: Apr 30, 2007 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

IMP supply

Other Hypertension trials with similar outcome

Browse all Hypertension trials

This PHASE2 trial investigates Hypertension and is currently terminated or withdrawn. Egalet Ltd leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Egalet Ltd

Data source: Egalet Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Esbjerg, Denmark
• Frederiksberg, Denmark